Celgene pays $177 million for cancer stem cell pact with OncoMed
This article was originally published in Scrip
Celgene is making a bet on therapies that target cancer stem cells, paying more than $177 million to potentially license experimental treatments from newly public biotech OncoMed Pharmaceuticals.
You may also be interested in...
Loss of anti-RSPO-3 antibody rosmantuzumab, partnered with Celgene, means a rough start to the year, following disappointments in 2017.
OncoMed lays off half its employees after a series of recent clinical setbacks. Meanwhile, six public companies raise $1.64bn in $100m-plus follow-on and debt offerings, SV Health Investors closed a $400m venture capital fund and eight therapeutics firms grabbed $247.5m in VC cash.
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.